PX-12

DRUG2 trials

Sponsors

Cascadian Therapeutics Inc.

Conditions

Advanced CancerMetastatic CancerPancreatic Neoplasms

Phase 1

A Trial of PX-12 in Patients With a Histologically or Cytologically Confirmed Diagnosis of Advanced or Metastatic Cancer

CompletedNCT00736372

Cascadian Therapeutics Inc.Advanced Cancer, Metastatic Cancer

Start: 2008-06-30End: 2009-08-31Updated: 2018-05-17

Phase 2

Phase II Study of PX-12 in Patients With Advanced Pancreatic Cancer

TerminatedNCT00417287

Cascadian Therapeutics Inc.Pancreatic Neoplasms

Start: 2006-12-31End: 2009-04-30Updated: 2018-05-16